Induction of T-cell memory subsets and inflammatory cytokines are associated with the pharmacodynamic profile of glofitamab. (A) Graphs represent Log₂ fold change (Log2FC) from baseline (C1D1 predose) of peripheral CD8⁺ T-cell subsets measured by flow cytometry on the first day (D1 predose) of the first 5 cycles. Error bars indicate confidence intervals. Data generated from n = 119 patients with evaluable flow cytometry data. (B) Plots show Log2FC from baseline (C1D1 predose) of CD8⁺ T-cell effector memory subsets measured by flow cytometry on the first day of cycle 3 (C3D1, predose) for the 4 to 25 mg dose cohort. The x-axes indicate the best overall response (BOR). Means of each response category are shown, and error bars indicate confidence intervals. P values >.05 for CR vs PR/stable disease (SD)/progressive disease (PD) and were not adjusted for log(glofitamab dose) and IPI category. (C) Plasma cytokine concentrations (pg/mL) of IFN-γ, IL-6, and IL-2 are shown at indicated time points, including before obinutuzumab pretreatment and during the first cycle before infusion, mid-infusion (MI), and end of infusion (EOI). Data generated from n = 119 patients with evaluable cytokine data. The y-axes are in logarithmic scales. Error bars indicate standard error of the mean. In panels A and B, dotted lines indicate baseline levels, and dashed lines indicate twofold change from baseline. 6 H EOI, 6 hours post-end of infusion; C, cycle; D, day; Gz, obinutuzumab; CD45RA−CD197−, Tem; CD45RA+CD197−, Temra.